Prem Watsa
Fairfax Financial Holdings
Prem Watsa Cellular Biomedicine Group Inc stake
total: 291
Fairfax Financial Holdings CBMG trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2020 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2021 Q1
According to 2026 Q2 report, Prem Watsa doesn't hold any Cellular Biomedicine Group Inc (CBMG) shares. To date, the estimated cost basis is nearly $18.37 for "buy" trades and estimated average "sell" price is $18.37. Fairfax Financial Holdings first purchased CBMG in 2020 Q4, initially acquiring 8,600 shares. Since the initial investment in Cellular Biomedicine Group Inc (CBMG), Fairfax Financial Holdings has made 1 more transaction.
When did Prem Watsa sell Cellular Biomedicine Group Inc (CBMG)?
Prem Watsa sold off the entire Cellular Biomedicine Group Inc (CBMG) position in 2021 Q1.
When did Prem Watsa buy Cellular Biomedicine Group Inc (CBMG)?
Prem Watsa first invested in Cellular Biomedicine Group Inc (CBMG) in 2020 Q4 at the reported quarter-end price of $18.37 per share.
What's the cost basis of Fairfax Financial Holdings's CBMG stake?
The estimated cost basis for Cellular Biomedicine Group Inc (CBMG) stake is around $18.37 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $18.37
- Weighted AVG sell price:
- $18.37
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.